Chronic Hand Eczema (CHE) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

 Chronic Hand Eczema (CHE) is defined as either a long-term, relapsing course of HE or HE that is unresponsive to standard treatment with emollients and topical corticosteroids for more than three months or recurrence of symptoms twice within a year despite treatment. Clinical signs and symptoms of Chronic Hand Eczema comprise classic features of eczema localized to the hands and fingers, including dryness, erythema, edema, hyperkeratosis, scaling, lichenification, vesiculation/ blistering, fissures, pruritus, and pain. Eczema and dermatitis are used as synonyms. Both terms are used interchangeably to describe a particular type of inflammatory disorder of the skin that targets the epidermis and the dermis. Acute and subacute HE can be defined as eczema, localized to the hands, that lasts for less than three months and does not occur more than once per year. In the acute stage, vesicles will be present in most cases, although not always in irritant HE. Erythema, representing inflammation, is pronounced in acute HE, as is edema. A subjective sensation of burning and itching is present in most cases. Chronic HE refers to an eczematous process that lasts for more than three months or relapses twice or more often per year. Scaling and fissures are found in most cases. Hyperkeratosis is present in chronic irritant and allergic HE but is also found in the endogenous hyperkeratotic HE and other chronic patients.

 

The prevalence of Chronic Hand Eczema (CHE) varies from 540 to 629 per 100,000 population in the USA.

 

The competitive landscape of Chronic Hand Eczema (CHE) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Chronic Hand Eczema (CHE) across the 8 MM market from the center of Excellence/ Public/ Private hospitals participated. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Chronic Hand Eczema (CHE) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Chronic Hand Eczema (CHE) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          Delgocitinib       LEO Pharma     Phase 3

2          Ruxolitinib         Incyte Corporation         Phase 2

3          ARQ-252          Arcutis Biotherapeutics, Inc.       Phase 2

4          alitretinoin         Stiefel, a GSK Company            Phase 3

5          ASN002            Asana BioSciences        Phase 2